Global Live Attenuated Vaccines Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033

Description

List of Tables

Global Live Attenuated Vaccines Market is poised for a significant growth, with market size projected to surge from USD 21.23 Billion in 2024 to USD 52.91 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 10.68% during the forecast period.

The global live attenuated vaccines market is set for robust growth driven by increasing immunization programs and demand for effective, long-lasting immunity against infectious diseases. Advances in genetic engineering and viral vector technologies are enabling development of safer, more targeted live attenuated vaccines. Future innovations will focus on thermostable formulations and needle-free delivery systems to improve accessibility and compliance.

Moreover, the COVID-19 pandemic has accelerated vaccine research and manufacturing capacity expansion. Growing awareness and government initiatives in emerging markets are expanding vaccination coverage. Regulatory harmonization and public-private partnerships are facilitating market entry and distribution. As global health priorities evolve, the live attenuated vaccines market will continue to innovate, delivering safe, efficacious, and accessible immunization solutions.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

LIST OF SEGMENTS COVERED

This section of the Live Attenuated Vaccines market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Vaccine Type

Bacterial Vaccine
Viral Vaccine

By Development

Tissue Culture
Embryonated Eggs
Live Animals

By Mode Of Administration

Oral
Injectable
Intranasal

By Age Group

Pediatric
Adult

By Indication

Tuberculosis
Measles
Rotavirus
Yellow Fever
Oral Polio
Influenza
Other Indications

By End-Use

Hospitals (Public, Private)
Specialty Clinics
Other End-Users
List of Companies Profiled in the report
Abbott, Bharat Biotech International Limited, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Haffkine Biopharmaceutical Corporation Limited, HBI, Merck & Co., Novartis Pharmaceuticals Corporation, Sanofi, Serum Institute of India Ltd., Valneva SE, Zydus Group.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112114275

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. LIVE ATTENUATED VACCINES - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Vaccine Type
- 3.7.2 Market Attractiveness Analysis By Development
- 3.7.3 Market Attractiveness Analysis By Mode Of Administration
- 3.7.4 Market Attractiveness Analysis By Age Group
- 3.7.5 Market Attractiveness Analysis By Indication
- 3.7.6 Market Attractiveness Analysis By End-Use
- 3.7.7 Market Attractiveness Analysis By Regions

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL LIVE ATTENUATED VACCINES MARKET ANALYSIS BY VACCINE TYPE

5.1. Overview By Vaccine Type
5.2. Historical and Forecast Data Analysis By Vaccine Type
5.3. Bacterial Vaccine Historic and Forecast Sales By Regions
5.4. Viral Vaccine Historic and Forecast Sales By Regions

6. GLOBAL LIVE ATTENUATED VACCINES MARKET ANALYSIS BY DEVELOPMENT

6.1. Overview By Development
6.2. Historical and Forecast Data Analysis By Development
6.3. Tissue Culture Historic and Forecast Sales By Regions
6.4. Embryonated Eggs Historic and Forecast Sales By Regions
6.5. Live Animals Historic and Forecast Sales By Regions

7. GLOBAL LIVE ATTENUATED VACCINES MARKET ANALYSIS BY MODE OF ADMINISTRATION

7.1. Overview By Mode Of Administration
7.2. Historical and Forecast Data Analysis By Mode Of Administration
7.3. Oral Historic and Forecast Sales By Regions
7.4. Injectable Historic and Forecast Sales By Regions
7.5. Intranasal Historic and Forecast Sales By Regions

8. GLOBAL LIVE ATTENUATED VACCINES MARKET ANALYSIS BY AGE GROUP

8.1. Overview By Age Group
8.2. Historical and Forecast Data Analysis By Age Group
8.3. Pediatric Historic and Forecast Sales By Regions
8.4. Adult Historic and Forecast Sales By Regions

9. GLOBAL LIVE ATTENUATED VACCINES MARKET ANALYSIS BY INDICATION

9.1. Overview By Indication
9.2. Historical and Forecast Data Analysis By Indication
9.3. Tuberculosis Historic and Forecast Sales By Regions
9.4. Measles Historic and Forecast Sales By Regions
9.5. Rotavirus Historic and Forecast Sales By Regions
9.6. Yellow Fever Historic and Forecast Sales By Regions
9.7. Oral Polio Historic and Forecast Sales By Regions
9.8. Influenza Historic and Forecast Sales By Regions
9.9. Other Indications Historic and Forecast Sales By Regions

10. GLOBAL LIVE ATTENUATED VACCINES MARKET ANALYSIS BY END-USE

10.1. Overview By End-Use
10.2. Historical and Forecast Data Analysis By End-Use
10.3. Hospitals (Public, Private) Historic and Forecast Sales By Regions
10.4. Specialty Clinics Historic and Forecast Sales By Regions
10.5. Other End-Users Historic and Forecast Sales By Regions

11. GLOBAL LIVE ATTENUATED VACCINES MARKET ANALYSIS BY GEOGRAPHY

11.1. Regional Outlook
11.2. Introduction
11.3. North America Sales Analysis
- 11.3.1 Overview, Historic and Forecast Data Sales Analysis
- 11.3.2 North America By Segment Sales Analysis
- 11.3.3 North America By Country Sales Analysis
- 11.3.4 United States Sales Analysis
- 11.3.5 Canada Sales Analysis
- 11.3.6 Mexico Sales Analysis
11.4. Europe Sales Analysis
- 11.4.1 Overview, Historic and Forecast Data Sales Analysis
- 11.4.2 Europe By Segment Sales Analysis
- 11.4.3 Europe By Country Sales Analysis
- 11.4.4 United Kingdom Sales Analysis
- 11.4.5 France Sales Analysis
- 11.4.6 Germany Sales Analysis
- 11.4.7 Italy Sales Analysis
- 11.4.8 Russia Sales Analysis
- 11.4.9 Rest Of Europe Sales Analysis
11.5. Asia Pacific Sales Analysis
- 11.5.1 Overview, Historic and Forecast Data Sales Analysis
- 11.5.2 Asia Pacific By Segment Sales Analysis
- 11.5.3 Asia Pacific By Country Sales Analysis
- 11.5.4 China Sales Analysis
- 11.5.5 India Sales Analysis
- 11.5.6 Japan Sales Analysis
- 11.5.7 South Korea Sales Analysis
- 11.5.8 Australia Sales Analysis
- 11.5.9 South East Asia Sales Analysis
- 11.5.10 Rest Of Asia Pacific Sales Analysis
11.6. Latin America Sales Analysis
- 11.6.1 Overview, Historic and Forecast Data Sales Analysis
- 11.6.2 Latin America By Segment Sales Analysis
- 11.6.3 Latin America By Country Sales Analysis
- 11.6.4 Brazil Sales Analysis
- 11.6.5 Argentina Sales Analysis
- 11.6.6 Peru Sales Analysis
- 11.6.7 Chile Sales Analysis
- 11.6.8 Rest of Latin America Sales Analysis
11.7. Middle East & Africa Sales Analysis
- 11.7.1 Overview, Historic and Forecast Data Sales Analysis
- 11.7.2 Middle East & Africa By Segment Sales Analysis
- 11.7.3 Middle East & Africa By Country Sales Analysis
- 11.7.4 Saudi Arabia Sales Analysis
- 11.7.5 UAE Sales Analysis
- 11.7.6 Israel Sales Analysis
- 11.7.7 South Africa Sales Analysis
- 11.7.8 Rest Of Middle East And Africa Sales Analysis

12. COMPETITIVE LANDSCAPE OF THE LIVE ATTENUATED VACCINES COMPANIES

12.1. Live Attenuated Vaccines Market Competition
12.2. Partnership/Collaboration/Agreement
12.3. Merger And Acquisitions
12.4. New Product Launch
12.5. Other Developments

13. COMPANY PROFILES OF LIVE ATTENUATED VACCINES INDUSTRY

13.1. Top Companies Market Share Analysis
13.2. Market Concentration Rate
13.3. Abbott
- 13.3.1 Company Overview
- 13.3.2 Company Revenue
- 13.3.3 Products
- 13.3.4 Recent Developments
13.4. Bharat Biotech International Limited
- 13.4.1 Company Overview
- 13.4.2 Company Revenue
- 13.4.3 Products
- 13.4.4 Recent Developments
13.5. Boehringer Ingelheim International GmbH
- 13.5.1 Company Overview
- 13.5.2 Company Revenue
- 13.5.3 Products
- 13.5.4 Recent Developments
13.6. GlaxoSmithKline Plc
- 13.6.1 Company Overview
- 13.6.2 Company Revenue
- 13.6.3 Products
- 13.6.4 Recent Developments
13.7. Haffkine Biopharmaceutical Corporation Limited
- 13.7.1 Company Overview
- 13.7.2 Company Revenue
- 13.7.3 Products
- 13.7.4 Recent Developments
13.8. HBI
- 13.8.1 Company Overview
- 13.8.2 Company Revenue
- 13.8.3 Products
- 13.8.4 Recent Developments
13.9. Merck & Co.
- 13.9.1 Company Overview
- 13.9.2 Company Revenue
- 13.9.3 Products
- 13.9.4 Recent Developments
13.10. Novartis Pharmaceuticals Corporation
- 13.10.1 Company Overview
- 13.10.2 Company Revenue
- 13.10.3 Products
- 13.10.4 Recent Developments
13.11. Sanofi
- 13.11.1 Company Overview
- 13.11.2 Company Revenue
- 13.11.3 Products
- 13.11.4 Recent Developments
13.12. Serum Institute Of India Ltd.
- 13.12.1 Company Overview
- 13.12.2 Company Revenue
- 13.12.3 Products
- 13.12.4 Recent Developments
13.13. Valneva SE
- 13.13.1 Company Overview
- 13.13.2 Company Revenue
- 13.13.3 Products
- 13.13.4 Recent Developments
13.14. Zydus Group
- 13.14.1 Company Overview
- 13.14.2 Company Revenue
- 13.14.3 Products
- 13.14.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of privcompanies